ID: ALA5196602

Max Phase: Preclinical

Molecular Formula: C16H15N5O2

Molecular Weight: 309.33

Representations

Canonical SMILES:  CC(C)COc1ccc(-c2ncc3c(=O)[nH][nH]c3n2)cc1C#N

Standard InChI:  InChI=1S/C16H15N5O2/c1-9(2)8-23-13-4-3-10(5-11(13)6-17)14-18-7-12-15(19-14)20-21-16(12)22/h3-5,7,9H,8H2,1-2H3,(H2,18,19,20,21,22)

Standard InChI Key:  WCGNBOGQZBWIQF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 309.33

Molecular Weight (Monoisotopic): 309.1226

AlogP: 2.22

#Rotatable Bonds: 4

Polar Surface Area: 107.45

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.51

CX Basic pKa: 3.71

CX LogP: 3.37

CX LogD: 3.37

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.77

Np Likeness Score: -1.24

References

1. Zhao J, Mao Q, Lin F, Zhang B, Sun M, Zhang T, Wang S..  (2022)  Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.,  229  [PMID:34992040] [10.1016/j.ejmech.2021.114086]

Source

Source(1):

• Scientific Literature